Synnovation Therapeutics

Recent Finacing

Series A

Recent Raise

$102M

Synnovation Therapeutics develops precision small-molecule oncology therapies, advancing CNS-penetrant PARP1 inhibitor SNV1521 in Phase I and mutant-selective PI3K-alpha inhibitor SNV4818 targeting H1047X mutations.

Founded 2021

Delaware, United States

11-50

Private

synnovationtx.com

Highlights

Focus Areas

Biotechnology

Health Care

Life Science

Medical

Oncology

Recent Investors

Financials

$102M

Total Raised

1

Funding round

5

Investors

Team

Upgrade to view the team

See the team members at Synnovation Therapeutics.